Dr Brian Hon-Yin Chung (鍾侃言)

MBBS(Hons, HKU), MSc(Genomics and Bioinformatics, CUHK), MD(HKU)

DCH(Ireland), MRCPCH (UK), FHKAM(Paediatrics), FRCPCH(UK), FCCMG(Clinical Genetics, Canada)



Clinical Associate Professor

Department of Paediatrics and Adolescent Medicine,

Li Ka Shing Faculty of Medicine, The University of Hong Kong




Clinical Genetics & Genomics







(852) 2255-4482

(852) 2855-1523

Department of Paediatrics & Adolescent Medicine

Room 115, 1/F, New Clinical Building

102 Pokfulam Road, Queen Mary Hospital, Hong Kong


LinkedIn: www.linkedin.com/in/bhychung


Research ID


Google Scholar ID


Scopus ID

HKU Scholars Hub



  1. Outstanding Teaching Award, Teaching Excellence Awards, HKU (2019) [ click here to open from uvision ]


  2. Best Paper Award - Teaching and Learning Physical Examination in the Clinical Setting: Authentic Assessment of Multi-domain Competencies for Independent Professional Practice; 2019 World Federation for Medical Education World Conference (shared with Dr Pamela Lee)
  3. Sir Patrick Manson Gold Medal (2018) - Clinical application of whole-genome technologies on Paediatric-onset rare diseases
  4. Faculty Teaching Medal (2018) [ click here to open related document ]
  5. Audience Award, Free paper, Frontiers in Medical and Health Sciences Education (2018, shared with Dr Pamela Lee)
  6. Award of Merit, Free paper, Frontiers in Medical and Health Sciences Education (2018, shared with Dr Pamela Lee)
  7. Best Young Investigator Prize - Hong Kong College of Paediatricians (2017)
  8. Knowledge Exchange Awards 2017 - Little People Care Alliance; Li Ka Shing Faculty of Medicine (2017, shared)
  9. Long Service Awards, After 15 Years of Service; Department of Paediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong (2016)
  10. Outstanding Oral Presentation Award - Identifying genetic mutations in patients with RASopathies using a new generation sequencing diagnostic pipeline in Hong Kong; Annual Scientific Meeting 2013, Hong Kong College of Paediatricians (2013)
  11. Outstanding Poster Presentation Award - Integration of chromosomal microarray into paediatric clinical care in Hong Kong; Annual Scientific Meeting 2013, Hong Kong College of Paediatricians (2013)
  12. Certificate of Excellence - Master of Science in Genomics & Bioinformatics; Division of Genomics & Bioinformatics, CUHK-BGI Innovation Institute of Trans-omics (2013)
  13. Outstanding Team award - The Hong Kong West Cluster (2012)
  14. 10-year Loyalty Award - Queen Mary Hospital (2010)
  15. First Runner-up Best Poster Presentation - 7th Asia Pacific Medical Education Conference (APMEC) (2010)
  16. One of the Top 4 submissions - 34th Annual Scientific Meeting, Canadian College of Medical Genetics (2010)
  17. Best Basic Research - Annual Research Day, Paediatrics, Hospital for Sick Children, Toronto (2010)
  18. Fellow Award - 30th Annual David W. Smith Workshop on Malformations and Morphogenesis (2009 & 2010)
  19. Silver Medal in Best Original Research Contest - Clinical Markers Useful in Enhancing Diagnostic Yield for Children with Global Developmental Delay (GDD); HK Academy of Medicine (2005)
  20. Most Outstanding Free Paper - (SMARD1) Spinal muscular atrophy with respiratory distress type 1 mutation in a Chinese boy; The 3rd Hong Kong Genetic Symposium 2005 (2005)


Research Themes

My research focuses in three main areas: (1) Medical application of whole genome technologies, (2) Clinical genetics & genetic counselling and (3) Epigenetics & human diseases.


Medical application of whole-genome technologies


Genomic medicine is an emerging medical discipline that involves using genomic information about an individual as part of their clinical care and the health outcomes and policy implications of that clinical use. Its impact in clinical care depends significantly on the successful translation and integration of cutting-edge whole genome technologies from bench to bedside. My research interest is on the clinical application of whole genome technologies in the diagnosis of rare genetic diseases in children. My work includes a series of investigations using Chromosomal Microarray (CMA) in the genetic evaluation of congenital malformations, neurodevelopmental disorders, and congenital heart disease. I have also recruited over 1200 patients in the HKU paediatric exome sequencing project in various clinical contexts (see Figure).


  Study Period Diagnosis
Undiagnosed Diseases
NPJ Genomic Medicine (2018)
Undiagnosed Diseases Reanalysis (12% additional yield)
NPJ Genomic Medicine (2020)
Autism with Macrocephaly
Molecular Autism (2017)
Drug Resistant Epilepsy
Epilepsia Open (2018)

Mitochondrial Disease

Human Genomics (2020)


Neuromuscular Disease
Molecular Genetics & Genomic Medicine (2020)
Movement Disorders
Orphanet Journal of Rare Diseases (2021)
Hong Kong Medical Journal (2018)
Prenatal diagnosis
BMC medical genomics (2018)
Critically ill patients and rapid diagnosis
Lancet Regional Health – Western Pacific (2020)


To facilitate the implementation of genomic medicine in Hong Kong, we have also investigated our data further for implications in pre-emptive pharmacogenomics testing, expanded carrier screening, and incidental findings.


Clinical Genetics & Genetic Counselling


As a clinical geneticist, I have contributed to the advancement of diagnosis, management, and genetic counselling. This is achieved by syndrome delineation, phenotype expansion, characterization of founder mutations and providing insights for improving the management and better understanding of molecular mechanisms. Through leading a consortium of researchers from 60 institutes across 11 countries, we characterized 23 cases and discovered a new syndrome named MN1 C-terminal truncation (MCTT) syndrome. We have also discovered a novel role of the CC2D1A gene in heterotaxy and ciliary dysfunction.


Founder mutations are often responsible for the high prevalence of rare genetic disorders in specific populations and they are ethnicity-specific and typically under-represented in genomic databases. We identified founder mutations in the COQ4 gene for primary coenzyme Q10 deficiency-7, CFTR gene for Cystic Fibrosis, ALMS1 gene for Alstrom syndrome and KLHL40 gene for Nemaline Myopathy type 8.


Novel mutations discovered are archived on the online Clinvar database (https://www.ncbi.nlm.nih.gov/clinvar/submitters/507009/) hosted by the NCBI (National Center for Biotechnology Information, U.S. National Library of Medicine).


Epigenetics and Human Disease


Epigenetics is the study of heritable changes in gene expression caused by mechanisms other than changes in the underlying DNA sequence. These epigenetic signatures are important in the study of rare and common diseases. Combining the use of exome sequencing and DNA methylation microarray, I have described the first ever human case of paternal uniparental disomy for chromosome 19, which is potentially a new imprinting disorder.


I am an active member of the International Epigene Consortium led by Prof Rosanna Weksberg of SickKids, Toronto. Our collaborative work has demonstrated disease-specific DNA methylation signature can be used to classify variants of uncertain significance, which was demonstrated in multiple genetic syndromes including Weaver syndrome and Sotos syndrome. I am also investigating the methylation changes in children with rare disease in Hong Kong, support by the Health and Medical Research Fund (HMRF) Commissioned Paediatric Research at Hong Kong Children’s Hospital (2020), under the project titled "Diagnostic utility of blood transcriptome and methylome in children with undiagnosed genetic conditions".


Beyond the epigenetics of rare diseases, my research team is also interested in studying DNA methylation in common diseases, particularly systemic lupus erythematosus (SLE) as it is common in Chinese


Selected publications


  • Yu MHC, Chan MCY, Chung CCY, Li AWT, Yip CYW, Mak CCY, Chau JFT, Lee M, Fung JLF, Tsang MHY, Chan JCK, Wong WHS, Yang J, Chui WCM, Chung PHY, Yang W, Lee SL, Chan GCF, Tam PKH, Lau YL, Tang CSM, Yeung KS, Chung BHY. Actionable pharmacogenetic variants in Hong Kong Chinese exome sequencing data and projected prescription impact in the Hong Kong population. PLoS Genet. 2021 Feb 18;17(2):e1009323. (IF 5.714) Link
    In this study utilizing exome sequencing data of 1116 Hong Kong Chinese subjects, we studied the pharmacogenetics of the local population. We investigated the spectrum of 133 actionable pharmacogenetic variants and rare deleterious variants in 108 pharmacogenes. It was found that nearly all individuals carried at least one actionable pharmacogenetic variant and one rare, predicted deleterious pharmacogenetic variant. In addition, we projected the potential prescription impact of actionable pharmacogenetic variants using prescription data of Hong Kong's public healthcare system. We estimated that one-seventh of the Hong Kong population received at least one of the 36 drugs with clinical pharmacogenetics guideline recommendations. The findings demonstrated the potential of pharmacogenetic testing in improving patient care and resource allocation in Chinese. The study was quoted by the PHG foundation of the University of Cambridge: https://www.phgfoundation.org/blog/international-lessons-for-personalised-medicine


  • Yu MHC, Chau JFT, Au SLK, Lo HM, Yeung KS, Fung JLF, Mak CCY, Chung CCY, Chan KYK, Chung BHY, Kan ASY. Evaluating the Clinical Utility of Genome Sequencing for Cytogenetically Balanced Chromosomal Abnormalities in Prenatal Diagnosis. Front Genet. 2021 Jan 27;11:620162. (IF 3.789) Link
    In this pilot project, we looked at balanced chromosomal abnormalities (BCAs) which occur at a frequency of 1 in 500 newborns and are associated with an increased risk of multiple congenital anomalies and/or neurodevelopmental disorders. We used short read genome sequencing (GS) to retrospectively re-sequence ten prenatal subjects with de novo BCAs and compared the performance of GS with the original karyotyping. GS characterized all BCAs found by conventional karyotyping with the added benefit of precise sub-band delineation. We demonstrated that the additional information gained from GS can provide a more specific genetic diagnosis and change the interpretation of the BCAs and therefore using GS for the diagnosis of BCAs would have added clinical utility compared to karyotyping.


  • Ma ACH, Mak CCY, Yeung KS, Pei SLC, Ying D, Yu MHC, Hasan KMM, Chen X, Chow PC, Cheung YF, Chung BHY. Monoallelic Mutations in CC2D1A Suggest a Novel Role in Human Heterotaxy and Ciliary Dysfunction. Circulation: Precision and Genomic Medicine. 2020 Dec;13(6):e003000. (IF 4.063) Link
    In this publication, a novel gene CC2D1A was found to be associated with human heterotaxy and ciliary defects. The novel finding provides insights into the complex genetic causes of congenital heart defects (left and right isomerism) and demonstrates the potential of the zebrafish animal model to validate novel candidate genes identified from next generation sequencing.
    By using whole exome sequencing and gene burden analysis, a significant enrichment of novel rare damaging mutations in the CC2D1A gene was identified. The CC2D1A gene is a transcription factor which has only previously been associated with intellectual disability and autism spectrum disorders but not heterotaxy. The function of this gene was further examined by use of a TALEN-mediated zebrafish knock-out model. Abnormalities of cardiovascular and gastrointestinal systems with relation to the left-right axis were identified in both somatic and germline mutants. By whole-mount immunostaining of acetylated α-tubulin, defective cilia were also identified in the mutants.


  • Yu MHC, Mak CCY, Fung JLF, Lee M, Tsang MHY, Chau JFT, Chung PH, Yang W, Chan GCF, Lee SL, Lau YL, Tam PKH, Tang CSM, Yeung KS, Chung BHY. Actionable secondary findings in 1116 Hong Kong Chinese based on exome sequencing data. J Hum Genet. 2020 Nov 22:1-5. Link (IF 2.813)
    In this project, primary data from whole exome sequencing was used to look for actionable secondary findings that offer medical benefit for patient care. In a cohort of 1116 Hong Kong Chinese individuals, we evaluated the secondary findings in the 59 genes recommended by the American College of Medical Genetics and Genomics. Fifteen unique pathogenic or likely pathogenic variants in 17 individuals were identified, representing a frequency of 1.52% in our cohort. Although 20 individuals harboured pathogenic or likely pathogenic variants in recessive conditions, none carried bi-allelic mutations in the same gene. Our finding was in accordance with the estimation from the American College of Medical Genetics and Genomics that about 1% individuals harbour secondary findings.


  • Chau JFT, Chung CCY, Yu MHC, Yeung KS, Chung BHY. “Rare” Monogenic Variants in Severe COVID-19 cases. Science. (e-Letter, 2020 Nov 19) Link (IF 41.846)
    In this project, we performed an extensive population genomic analysis on potentially deleterious rare monogenic variants identified in Zhang et al (2020) associated with life-threatening COVID-19 infection. We found that amongst the 24 variants identified in the study, the autosomal dominant variants TICAM1 p.Ser60Cys and IFNAR1 p.Pro335del variants identified had a higher allelic frequency of 0.0041 and 0.0049, respectively in the East Asians (gnomAD_EAS) and 0.0100 and 0.0053, respectively in our Hong Kong Chinese Control database than other ethnicities. With the use of Hardy-Weinburg Equilibrium, this implied that 1.79% to 3.02% of the population would have a susceptibility to develop a severe life-threatening COVID-19 phenotype. Our findings emphasize that East Asian populations should be used for in-depth investigations of penetrance and expressivity of these variants, and their roles in developing life-threatening COVID-19 pneumonia.


  • Chung CCY, Leung GKC, Mak CCY, Fung JLF… Lau YL, Chan GCF, Lee SL, Yeung KS, Chung BHY. Rapid whole-exome sequencing facilitates precision medicine in paediatric rare disease patients and reduces healthcare costs. The Lancet Regional Health-Western Pacific. 2020 Aug 1;1:100001. Link (IF pending)
    This study is the largest prospectively ascertained cohort in using rWES for patients with suspected monogenic disorder that focused on the impact of clinical management and its actual costs-savings. Our study demonstrated rWES achieved a diagnostic yield of 31% with a median TAT of 11 days, comparable to international studies. Importantly, rWES aided clinical management in 88% of diagnosed patients in this cohort, which is higher than most of the published studies. We also demonstrated rWES reduced healthcare expenditure and achieved net healthcare cost-savings of HKD$5,325,187 in the clinical setting. This study has recently been published in the first issue of The Lancet Regional Health – Western Pacific, and was highlighted in the journal’s Editorial entitled “A new voice for the Western Pacific Region” (doi: 10.1016/j.lanwpc.2020.100015), and reported in the Cambridge Public Health Genomics webpage (https://www.phgfoundation.org/blog/rapid-exome-sequencing-for-paediatric-precision-medicine).


  • Mak CCY, Doherty D, Lin AE, Vegas N, Cho MT, Viot G, Dimartino C, Weisfeld-Adams JD, Lessel D, Joss S, Li C, Gonzaga-Jauregui C, Zarate YA, Ehmke N, Horn D, Troyer C, Kant SG, Lee Y, Ishak GE, Leung G, Barone Pritchard A, Yang S, Bend EG, Filippini F, Roadhouse C, Lebrun N, Mehaffey MG, Martin PM, Apple B, Millan F, Puk O, Hoffer MJV, Henderson LB, McGowan R, Wentzensen IM, Pei S, Zahir FR, Yu M, Gibson WT, Seman A, Steeves M, Murrell JR, Luettgen S, Francisco E, Strom TM, Amlie-Wolf L, Kaindl AM, Wilson WG, Halbach S, Basel-Salmon L, Lev-El N, Denecke J, Vissers LELM, Radtke K, Chelly J, Zackai E, Friedman JM, Bamshad MJ, Nickerson DA; University of Washington Center for Mendelian Genomics, Reid RR, Devriendt K, Chae JH, Stolerman E, McDougall C, Powis Z, Bienvenu T, Tan TY, Orenstein N, Dobyns WB, Shieh JT, Choi M, Waggoner D, Gripp KW, Parker MJ, Stoler J, Lyonnet S, Cormier-Daire V, Viskochil D, Hoffman TL, Amiel J, Chung BHY*, Gordon CT*. MN1 C-terminal truncation syndrome is a novel neurodevelopmental and craniofacial disorder with partial rhombencephalosynapsis. Brain. 2020;143(1):55-68. Link (IF 11.337) *Co-corresponding Author
    This study is an international collaboration co-led by HKU and Institut Imagine of France, involving genomic researchers from Asia, Europe and North America. Starting with a patient with an undiagnosed disease in the Duchess of Kent Children’s Hospital in Hong Kong, this journey has led to the discovery of a new neurodevelopmental syndrome caused by truncating mutations in the C-terminus of MN1 gene, a transcriptional regulator. We name this condition MN1 C-terminal truncation (MCTT) syndrome. We utilized state-of-the-art technologies including next generation sequencing, transcriptomics, and artificial intelligence neural network based facial recognition tool to characterize this new genetic disorder. This work also represents a breakthrough in our understanding of rhombencephalosynapsis (RES), a brain malformation characterized by partial or complete loss of the cerebellar vermis with fusion of the cerebellar hemispheres. RES was first described in medical literature in 1914 with no known animal models or consistent genetic causes reported. Our work has for the first time identified a genetic cause for RES and opens the door to understanding the pathophysiological mechanisms underlying RES and normal development of the cerebellum.
    An online registry has been established for MCTT syndrome and electronic articles have also been published:
    Online Registry for MN1 gene (https://humandiseasegenes.nl/mn1/)
    GeneReviews® (https://www.ncbi.nlm.nih.gov/books/NBK560443/)
    National Organization for Rare Disorders (NORD) (https://rarediseases.org/rare-diseases/mn1-c-terminal-truncation-syndrome/)
    POSSUMweb dysmorphology database (https://www.possumcore.com/ - Syndrome 7348)


  • Yu MHC, Tsang MHY, Lai S, Ho MSP, Tse DML, Wills B, Kwon gAKY, Chou YY, Lin SP, Quinzli CM, Hwu WL, Chien YH, Kuo PL, Chan VCM, Tsoi C,, Chong SC, Rodenburg RJT, Smeitink J, Mak CCY, Yeung KS, Fung JLF, Lam W, Hui J, Lee NC, Fung CW, Chung BHY. Primary coenzyme Q10 deficiency-7: expanded phenotypic spectrum and a founder mutation in southern Chinese. NPJ Genomic Medicine 2019; 4:18. Link (IF 5.631)
    In this study, we performed detailed analysis on the largest case series worldwide harbouring mutations of primary coenzyme Q10 deficiency-7. We found that mutations in the COQ4 gene are the most common molecular diagnosis in mitochondrial disease in Hong Kong, and the predominance of Chinese subjects in this cohort led to the discovery of a founder mutation c.370G>A. Founder mutations are often responsible for the high prevalence of rare genetic disorders in specific populations but are also associated with more common monogenic disorders and complex traits. These founder mutations are ethnicity-specific and are typically not described or under-represented in genomic databases.


  • Zayts O, Shipman H, Fung JLF, Liu APY, Kwok SY, Tsai ACH, Yung TC, Chung BHY. The different facets of "culture" in genetic counseling: A situated analysis of genetic counseling in Hong Kong. Am J Med Genet C Semin Med Genet. 2019;181(2):187-195. Link (IF 7.101)
    This research work was included in the issue “Clinical Genetics in Asia”, AJMG Part C in June 2019 where I was invited as a guest editor in-charge (https://onlinelibrary.wiley.com/toc/15524876/2019/181/2). This work is unique as it is a situated analysis on real life data in HK (HKU joint cardiac genetic clinic) and demonstrates the uniqueness of genetic counseling in HK with the cultural difference. This inter-disciplinary work on medicine and linguistics is one of the flagship projects of the newly established “Research and Impact Initiative on Communication in Healthcare in HKU”. This resulted from a long-term collaboration with the School of English which has been awarded a 2013 Faculty Knowledge Exchange award in HKU (http://arts.hku.hk/knowledge-exchange/faculty-ke-award/the-language-of-genetic-counselling). The unique research findings from our projects are extremely relevant to the practice of genetic counselling in HK, thus are applied into our teaching in the HKU Master of Medical Sciences curriculum for genetic counselling in which I serve as a programme director. With my current role as the President Elect for the Asia Pacific Society of Human Genetics, this special issue facilitated collaborations between HK and the regions of China, Singapore, Japan, Taiwan, Thailand, the Philippines, Malaysia etc. The special issue included four papers from HK to strengthen connections of HK with the region. As I highlighted in the editorial introduction, the aim of this special issue is to show “Asia's readiness and willingness to be a part of more international conversations about genetics in future.”


  • Chiu ATG, Chung CCY, Wong WHS, Lee SL, Chung BHY. Healthcare burden of rare diseases in Hong Kong–adopting ORPHAcodes in ICD-10 based healthcare administrative datasets. Orphanet Journal of Rare Diseases. 2018 Dec 1;13(1):147. Link (IF 3.523)
    In this study, we have set out to cross reference ORPHA codes and ICD-10 to identify rare diseases-related admissions in health administrative datasets in Hong Kong. In the 7-million populations, the prevalence of rare diseases was found to be 1 in 67, representing 1.5% of the whole population. This placed the estimated total inpatient cost for rare disease population at HKD$1,594,339,530 i.e. 4.3% of total inpatient cost in 2015-2016. The disparity reflects the importance of rare diseases in healthcare policies. This study for the first time provides information on healthcare burden of rare diseases in Hong Kong.


  • Yeung KS, Ho MSP, Lee SL, Kan ASY, Chan KYK, Tang MHY, Mak CCY, Leung GKC, So PL, Pfundt R, Marshall CR, Scherer SW, Choufani S, Weksberg R, Chung BHY. Paternal uniparental disomy of chromosome 19 in a pair of monochorionic diamniotic twins with dysmorphic features and developmental delay. Journal of Medical Genetics 2018;55(12):847-852 Link (IF 4.943)
    Uniparental disomy (UPD) occurs when a person obtains both copies of the homologous chromosome from one parent. UPD can be associated with human diseases caused by disruption of genomic imprinting or homozygosity for a recessive trait. In this report, we describe the first human case of paternal UPD for chromosome 19 in monozygotic twins showing dysmorphic features and global developmental delay. Comprehensive genetics and DNA methylation analysis suggested that imprinting defects were considered a potentially important mechanism to explain the clinical features of the twins.


  • Mak CCY, Leung GKC, Mok GTK, Yeung KS, Yang W, Fung CW, Chan SHS, Lee SL, Lee NC, Pfundt R, Lau YL, Chung BHY. Exome sequencing for paediatric-onset diseases: impact of the extensive involvement of medical geneticists in the diagnostic odyssey. NPJ Genom Med. 2018;3:19. Link (IF 5.631)
    As described by the journal’s editorial summary titled “Pediatrics: Extra Review of exome data boosts diagnostic yield”: In-depth reviews by clinical geneticists can improve the diagnostic accuracy of exome sequencing data for children with unexplained genetic disorders, especially in non-Western populations that are under-represented in genomic databases. Working with children predominantly of Han Chinese origin, Brian Chung from the University of Hong Kong and coworkers sequenced the entire protein-coding portion of the genome for 104 patients with pediatric-onset genetic disease. Specially trained geneticists analyzed the DNA data to resolve any ambiguous interpretations, link the molecular findings with clinical records, identify ethnic-specific differences and, when necessary, request additional assays. This extra review process was sometimes laborious, taking several hours of the physician’s time, but ultimately led to a more comprehensive assessment in 16 of the 43 diagnoses successfully made. This overall diagnostic yield—41%—was comparable to previous studies in other populations.
    Our team has finished “A three-year follow-up study evaluating the clinical utility of exome sequencing and diagnostic potential of exome reanalysis” on the same cohort of patients. In collaboration with Yale School of Medicine, we performed exome reanalysis in 46 undiagnosed individuals and achieved 12 new diagnoses. The additional yield compared with the initial analysis was at least 12% (increased from 41% to at least 53%). After a median follow-up period of 3.4 years, change in clinical management was observed in 72.2% of the individuals (26/36), leading to positive change in clinical outcome in four individuals (11%). There was a minimum healthcare cost saving of HKD$152,078 (USD$19,497; €17,282) annually for these four individuals. This three-year follow-up study demonstrated the long-term clinical utility of ES at individual, familial and health system level, and the promising diagnostic potential of subsequent reanalysis. This work has just been accepted in the npj Genomic Medicine for publication.


  • Yeung KS, Tso WWY, Ip JJK, Mak CCY, Leung GKC, Tsang MHY, Ying D, Pei SLC, Lee SL, Yang W, Chung BHY. Identification of mutations in the PI3K-AKT-mTOR signalling pathway in patients with macrocephaly and developmental delay and/or autism. Molecular Autism 2017; 8:66.Link (IF 5.869)
    This study illustrated that in patients with autism and/or developmental delay who also have macrocephaly, mutations in the PI3K-AKT-mTOR signalling pathway can be identified in nearly half of them. Both germline and somatic mosaicism can be the cause. This study showed that genetic testing should not be limited to PTEN, but also other genes in the PI3K-AKT-mTOR signalling pathway. In addition, sequencing should be performed with higher sequencing depth and in other tissues in order to detect low level of mosaicism. In a meta-analysis by Srivastava S et al. (Genetics in Medicine 2019; 21:2413-2421), our study was included as one of the 30 studies (from 973 articles) selected, and the review demonstrates that ES consistently outperforms chromosome microarray for the evaluation of unexplained neurodevelopmental disorders (NDDs). This results in a consensus statement suggesting ES as the first-tier clinical diagnostic test for individuals with NDDs.


  • Mak ASL, Chiu ATG, Leung GKC, Mak CCY, Chu YWY, Mok GTK, Tang WF, Chan KYK, Tang MHY, Lau ETK, So KW, Tao VQ, Fung CW, Wong VCN, Uddin M, Lee SL, Marshall CR, Scherer SW, Kan ASY, Chung BHY. Use of clinical chromosomal microarray in Chinese patients with autism spectrum disorder-implications of a copy number variation involving DPP10. Molecular Autism. 2017;8:31. Link (IF 5.869)
    To our knowledge this is the 3rd study on CNVs in Chinese with ASD, and the largest series reporting on DPP10-related CNV in normal individuals. The results have not only substantiated the genetic heterogeneity inherent to ASD, but also allowed for the reclassification of DPP10-related CNVs as a Chinese specific copy number polymorphism. Our findings illustrated the importance of using ancestry-matched controls and keeping a local genomic database when characterizing the clinical relevance of rare genetic variants in a population. I was awarded the Best Young Investigator Prize by the Hong Kong College of Paediatricians in 2017.


  • Choufani, S, Cytrynbaum C, Chung BHY, Turinsky A, Grafodatskaya D, Chen YA, Cohen A, Dupuis L, Butcher D, Siu MT, Luk HM, Lo I, Lam S, Caluseriu O, Stavropoulos D, Reardon W, Mendoza-Londono R, Brudno M, Gibson W, Chitayat D, Weksberg R. NSD1 mutations generate a genome-wide DNA methylation signature. Nature Communications 2015;6:10207. Link (IF 12.12)
    After successfully identifying a germline DNA methylation signature in patient with mutation in KDM5C (*Grafodatskaya D, *Chung BHY et al. BMC Medical Genomics 2013;6:1-18), we herewith identified a NSD1-specific DNA methylation signature in Sotos Syndrome and that loss of function NSD1 mutation can deregulate the transcriptional balance of key developmental genes. My role is to recruit and analyze a Chinese-specific cohort of patients with Soto Syndrome for validation of finding in the primary cohort. This work opens a new field of research in evaluating the diagnostic utility of genome-wide DNA methylation in individuals with unsolved genetic syndromes. *Co-First Authors



Full publication list


Link to Google scholar


Link to Scopus scholar


Link to ResearchGate




Editorship or editorial board membership of scholarly journals


Impact factor: 7.101
ISI Journal Citation Reports ©
Ranking: 2019: 16/178
(Genetics & Heredity)

  2012 - 2016 Secretary, Editorial Board, Hong Kong Journal of Paediatrics (HKJP)
  2017 - now Associate Editor, Editorial Board, Hong Kong Journal of Paediatrics (HKJP)
  2015 - 2017 MeMember, Editorial Board, American Journal of Medical Genetics (Part A)
  2018 - now Associate Editor, Editorial Board, American Journal of Medical Genetics (Part A)
  2019 – now Member, editorial board, npj Genomic Medicine
  2019 – now Associate Editor, Genetic Epidemiology Section, BMC Medical Genetics
  2019 Guest editor, American Journal of Medical Genetics (Part C) Seminar series – June 2019 issue on Clinical Genetics in Asia

Review Editor, Editorial Board, Frontiers in Pediatrics

  2020 Review Editor, Editorial Board, Frontiers in Genetics  
  2021 - 2023

Review Editor, Editorial Board, Journal of Translational Genetics and Genomics






Professional Societies

  2019 - now  President-Elect, Asia Pacific Society of Human Genetics    





Dr Chung serves as the Education Committee Chairman of the Department since 2017 (co-chairman: Dr Pamela Lee).

He also serves as the Secretary of the Subspecialty Board of Genetics & Genomics of the Hong Kong College of Paediatricians.

Dr CHUNG has achieved the status of Fellow (FHEA) in recognition of attainment against the UK Professional Standards Framework for teaching and learning support in higher education.



Teaching philosophy


I believe great teachers provide the environment and insights for the students to learn proactively and independently. I believe that clinical educators shall go beyond content knowledge and foster critical thinking and problem-solving skills (clinical reasoning). It is also particularly important to be clear about the relevance of the learning process to clinical practice. I take every opportunity to make use of real-life scenarios e.g. use of real patients or personal experience to enhance the student learning process. I strongly believe that learning should be patient-centered, as we are training future doctors to manage patients not only professionally but also humanely.

1) The learning process begins by identifying the gaps in the student's mindset, knowledge, and skills such that the student recognizes areas for development. Through effective feedback and techniques of self-reflection, our future doctors are equipped for their journey of self-long learning.

2) The learner must understand the relevance of the information in the clinical care of the patients. The use of real-life experiences in clinical practice is a powerful tool to engrave the relevance of the knowledge to their future practice as a doctor.

3) The ultimate aim of learning is not to be a good student but a good doctor, someone that can be entrusted with the important responsibilities of the health of Hong Kong citizens.

As a student (1995-1999) and teacher (2000-present) growing up in HKU, I embrace HKU’s vision to provide a “total learning experience”. The key institutional educational aims (https://tl.hku.hk/tl/) matches a lot of my core values in teaching: critical intellectual inquiry, life-long learning, critical self-reflection, collaboration, global citizenship and advocacy for the improvement of human conditions. In recognition of my contribution to teaching and curriculum development, I was awarded the Faculty Teaching Award in 2018-2019.


Teaching in Clinical Genetics


Click here to open the web resource for Teaching in Clinical Genetics ( *password needed to open this page )




Clinical Service


Clinical Genetics 臨床遺傳科




Knowledge Exchange


Media Coverage of Research: 



Media coverage on the identification of rarely documented pharmacogenetic variants in Hong Kong Chinese

- University of Cambridge PHG Foundation: International lessons for personalised medicine
- HKUMed: HKUMed identifies rarely documented pharmacogenetic variants commonly found among Hong Kong Chinese, highlighting the potential for personalised medicine
- 頭條日報: 港大醫學院發現港人帶有罕見基因變異 或影響不良反應及藥效
- 經濟日報: 港大發現99.6%港人基因對最少一種藥物過敏 倡記錄病人對本地36種常用藥物基因測試增處方藥成效
- 東網: 港大研究揭港人有罕見基因變異 或影響藥效及不良藥物反應
- 經濟一周: 港人多款常用藥受基因變異影響 港大:個人藥物處方減不良反應
- 香港商報: 港大醫學院以香港華人為對象研究與藥物有關的基因變異
- 巴士的報: 港大醫學院發現港人帶有罕見基因變異 或影響不良反應及藥效
- 經濟通: 9成9港華人帶基因變異,影響36種藥物藥效!邊3種藥最受影響?
- UrbanLife: 4歲腦癇女嚴重藥物過敏、全身皮膚潰爛似燒傷 港大研究:99.6%港人有影響藥物效果基因變異
- 星島: 港大醫學院發現港人帶有罕見基因變異 或影響不良反應及藥效
- AM730: 港人多款常用藥受基因變異影響 港大:個人藥物處方減不良反應
- 晴報 ULifestyle: 9成9港華人帶基因變異 影響藥效
- The Standard: Study boosts potential of personalized drugs
- 橙新聞: 指港人帶有罕見基因變異 港大:或引致藥物不良反應
- 關心您的心: 港人多款常用藥受基因變異影響 港大:個人藥物處方減不良反應
- 条条闻: 港大:香港人有罕见基因变异 对中国疫苗不良反应强烈
- 京港學術交流中心: 港大醫學院發現常見於香港華人但罕被記載而與藥物有關的基因變異 揭示個人化醫療潛力


Media coverage on the discovery of the novel gene CC2D1A for human heterotaxy.

- HKUMed: HKUMed discovers a novel gene in causing the rare disease “heterotaxy syndrome”
- Oriental Daily: 港大發現器官排列錯位是染色體作祟 有助病人作基因診斷
- AM 730: 治療曙光 罕見病「內臟錯位」 港大證涉基因異變
- HKET: 港大醫學院首次發現異位綜合症成因 冀助病人進行更精準基因診斷
- 晴報 ULifestyle: 港大揭基因異變 可致罕見內臟錯位
- Facebook: HKUMed discovers a novel gene in causing “heterotaxy syndrome”


Mention of rapid whole exome-sequencing (rWES) on the Cambridge Public Health Genomics Blog:

Rapid exome sequencing for paediatric precision medicine


Interview by Medical Outreachers:

Dr Brian Chung | Voices of Rare Disease


Other Media Coverage: (click below titles to open)

TVB Pearl: Pearl Report on “Rare Disease”
TVB 星期日檔案: 罕見疾病: 侏儒症 (Skeletal Dysplasia)
TVB: 黏多醣症與馬凡氏症 (Mucopoysaccharidosis and Marfan syndrome)

TVB: 週末主播室 - Rare Disease Day
香港電台鏗鏘集: 一個都不能少 (rare diseases)
Oriental Daily Health Column:- Fragile X Syndrome
至Fit 男女: 基因突變天使症 (Angelman syndrome)
Apple Daily Interview: 患小胖威利症  食唔停 (Prader Willi Syndrome)
RTHK: 港台精靈一點 - 亨廷頓舞蹈症 (Huntington’s chorea)
Commercial Radio: 調查指本港每67人就有1人患罕見疾病
Apple Daily TV: 全港逾10萬人患罕病 團體籲林鄭制訂全面政策
Metro Daily Hong Kong: 港大研究促政府確立罕見病定義
Oriental Daily News: 467種罕見病每67人有1病患 團體促加快藥物審批
香港01周報: 罕見病–上 - 患者平權路漫漫 - 政府如何衡量人命價值
香港01周報: 罕見病–下 - 實施全民醫保 - 為援助弱勢出路?
HKUMed Facebook 【香港守護者】罕見病專家鍾侃言(一):醫生最重要老實  (Hong Kong Guardian – rare disease expert Dr Brian Chung Part I)
HKUMed Facebook 【香港守護者】罕見病專家鍾侃言(二):明白易、接受難  (Hong Kong Guardian – rare disease expert Dr Brian Chung Part II)
HKUMed Facebook 【抗疫學堂】醫生,我想問……兒童限定版(上)(Fighting COVID19 – tips for children part 1) (174K views)
HKUMed Facebook 【抗疫學堂】醫生,我想問……兒童限定版(下)(Fighting COVID19 – tips for children part 2) (130k views)
Rare Disease Hong Kong (Call on government): COVID-19 Worsens Health Condition and Financial Status of Rare Disease Patients in Hong Kong Group Calls on Government to Respond Efficiently and Effectively






Undergraduate Research Students


MBBS Enrichment Year


Bachelor of Biomedical Science (BBMS Final Year Project) Students


Significant Achievement of Team Members


   "Every tree is known by its own fruit"




Dr. Winnie Tso, Assistant Professor (left), and
Dr. Steven Pei, Post-doctoral Fellow (right)
were both awarded the Young Investigator Award in The 13th Congress of Asian Society for Paediatric Research (ASPR) in 2017 under my supervision.

Miss Claudia Chung, PhD student, was awarded the Chen Travel Award at The 13th Asia Pacific Conference on Human Genetics (APCHG) in 2019 under my supervision. This was awarded to the best 10 students and young scientists in recognition of their outstanding research work at the conference. 


Miss Jasmine Fung was awarded the Best Poster Award in the 13th Asia Pacific Conference on Human Genetics (APCHG) in 2019 under my supervision.